Career history of Hans-Georg Capraro
Former positions of Hans-Georg Capraro
| Companies | Position | Start | End |
|---|---|---|---|
Oncalis AG
 Oncalis AG Pharmaceuticals: MajorHealth Technology Oncalis AG ('Oncology alliances') has been founded in June 2006 as a spin-off from ESBATech AG, a Swiss biotechnology company that has developed technology platforms in both the antibody and small molecule areas of pharmaceutical research. Oncalis has acquired from the mother company all small molecule-related assets, including a yeast-cell based, high- throughput screening platform for receptor tyrosine kinases (RTKs), and a number of specific and potent kinase inhibitors. The company is currently financed by ESBATech's Series A investors, including Novartis Venture Fund, BioMedInvest and Venture Incubator (VI) Partners. Oncalis will now focus on the discovery and development of small molecule inhibitors for oncology indications. | Corporate Officer/Principal | 15/05/2007 | 14/12/2011 |
| NOVARTIS AG | Corporate Officer/Principal | - | - |
Ciba-Geigy AG
 Ciba-Geigy AG Pharmaceuticals: MajorHealth Technology Ciba-Geigy AG was manufacturing pharmaceuticals. The company was merged with Sandoz Ltd. to create Novartis AG. The company was founded in 1884 and was headquartered in Basle, Switzerland. | Corporate Officer/Principal | - | - |
Training of Hans-Georg Capraro
| Swiss Federal Institute of Technology | Doctorate Degree |
Statistics
International
| Switzerland | 4 |
| Germany | 2 |
Operational
| Corporate Officer/Principal | 3 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| NOVARTIS AG | Health Technology |
| Private companies | 2 |
|---|---|
Oncalis AG
Oncalis AG Pharmaceuticals: MajorHealth Technology Oncalis AG ('Oncology alliances') has been founded in June 2006 as a spin-off from ESBATech AG, a Swiss biotechnology company that has developed technology platforms in both the antibody and small molecule areas of pharmaceutical research. Oncalis has acquired from the mother company all small molecule-related assets, including a yeast-cell based, high- throughput screening platform for receptor tyrosine kinases (RTKs), and a number of specific and potent kinase inhibitors. The company is currently financed by ESBATech's Series A investors, including Novartis Venture Fund, BioMedInvest and Venture Incubator (VI) Partners. Oncalis will now focus on the discovery and development of small molecule inhibitors for oncology indications. | Health Technology |
Ciba-Geigy AG
Ciba-Geigy AG Pharmaceuticals: MajorHealth Technology Ciba-Geigy AG was manufacturing pharmaceuticals. The company was merged with Sandoz Ltd. to create Novartis AG. The company was founded in 1884 and was headquartered in Basle, Switzerland. | Health Technology |
- Stock Market
- Insiders
- Hans-Georg Capraro
- Experience
